These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26834107)

  • 41. Review: Receptor Targeted Nuclear Imaging of Breast Cancer.
    Dalm SU; Verzijlbergen JF; De Jong M
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of Companion Diagnostics.
    Mankoff DA; Edmonds CE; Farwell MD; Pryma DA
    Semin Nucl Med; 2016 Jan; 46(1):47-56. PubMed ID: 26687857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
    Saúde-Conde R; Rasschaert G; Bregni G; Hendlisz A; Sclafani F
    Curr Opin Oncol; 2022 Jul; 34(4):382-388. PubMed ID: 35730499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer.
    Chen W; Li X; Zhu L; Liu J; Xu W; Wang P
    Cancer Biol Med; 2017 Aug; 14(3):271-280. PubMed ID: 28884043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept.
    Hou Y; Nitta H; Li Z
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.
    Ieni A; Cardia R; Pizzimenti C; Zeppa P; Tuccari G
    J Pers Med; 2020 Feb; 10(1):. PubMed ID: 32098203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unfortunate Accident or Blessing in Disguise? Dramatic Response to Incidental Intrathoracic Delivery of Anti-HER2 Regimen.
    Tariq K; Keen R; Draper K; Tang SC
    J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241190
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.
    Meng Q; Li Z
    Int J Biomed Imaging; 2013; 2013():230487. PubMed ID: 23533377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HER2 imaging in the ZEPHIR study.
    Clark AS; DeMichele A; Mankoff D
    Ann Oncol; 2016 Apr; 27(4):555-7. PubMed ID: 26802154
    [No Abstract]   [Full Text] [Related]  

  • 50. Detection of HER2 expression using
    Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
    Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
    Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
    J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.
    McGale J; Khurana S; Huang A; Roa T; Yeh R; Shirini D; Doshi P; Nakhla A; Bebawy M; Khalil D; Lotfalla A; Higgins H; Gulati A; Girard A; Bidard FC; Champion L; Duong P; Dercle L; Seban RD
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine.
    Miladinova D
    Front Mol Biosci; 2023; 10():1144817. PubMed ID: 36936995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer.
    Bragina OD; Deyev SM; Chernov VI; Tolmachev VM
    Acta Naturae; 2022; 14(2):4-15. PubMed ID: 35923562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
    Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
    Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
    [No Abstract]   [Full Text] [Related]  

  • 56. Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models.
    Wen L; Xia L; Guo X; Huang HF; Wang F; Yang XT; Yang Z; Zhu H
    Front Oncol; 2021; 11():778728. PubMed ID: 34869025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical Evaluation of
    Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I Study of
    Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
    J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.
    Garousi J; Orlova A; Frejd FY; Tolmachev V
    EJNMMI Radiopharm Chem; 2020 Jun; 5(1):16. PubMed ID: 32577943
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.